Related Experiment Videos
Now and future influenza vaccines
1University of Pittsburgh School of Medicine, Pennsylvania.
Abstract:
Influenza is a modern day plague. In the young, the clinical picture is classical, but in the elderly, the disease may go unsuspected until complications such as pneumonia develop. Influenza A and B viruses are responsible, and these viruses mutate with great regularity. Antibodies to the HA and NA surface antigens of influenza viruses, both naturally and vaccine induced, are protective. The earliest influenza vaccines were crude, toxic, and ineffective. With modern purification techniques, the egg-grown viruses have been turned into safe, immunogenic, and effective killed-virus vaccines--whole virus and split virus. Surveillance permits the correct virus strains to be incorporated into each new vaccine. Those who have been experiencing the worst effects of influenza have been identified. These individuals need to be immunized each year. In the future, live influenza virus vaccines may offer the benefits of ease of administration and longer-lasting protection. Synthetic peptides, genetically engineered antigens, and even nonantigen (anti-idiotype) vaccines are possible, but such vaccines will require adjuvant enhancement. For the present, greater efforts must be made to use existing influenza vaccines.
Insights
Influenza poses a significant health risk, particularly for the elderly, often leading to severe complications. Annual vaccination with safe and effective influenza vaccines is crucial for protection against mutating influenza A and B viruses.
Area of Science:
- Virology
- Immunology
- Public Health
Background:
- Influenza remains a significant global health concern, presenting classical symptoms in the young but often going undetected in the elderly until serious complications like pneumonia arise.
- Influenza A and B viruses are the primary causative agents, characterized by their high mutation rates, necessitating continuous vaccine development and updates.
- Protective immunity against influenza is primarily mediated by antibodies targeting the hemagglutinin (HA) and neuraminidase (NA) surface antigens.
Purpose of the Study:
- To review the evolution and efficacy of influenza vaccines.
- To highlight the importance of annual immunization, especially for vulnerable populations.
- To discuss future directions in influenza vaccine technology.
Main Methods:
- Review of historical and current influenza vaccine technologies, including whole virus and split virus vaccines.
- Discussion of influenza surveillance systems for vaccine strain selection.
- Exploration of emerging vaccine platforms such as live attenuated virus vaccines, synthetic peptides, and genetically engineered antigens.
Main Results:
- Modern purification techniques have transformed egg-grown influenza viruses into safe, immunogenic, and effective killed-virus vaccines.
- Ongoing surveillance is essential for selecting appropriate virus strains for annual vaccine formulation.
- Current influenza vaccines, while effective, require annual administration, particularly for high-risk individuals.
Conclusions:
- Existing inactivated influenza vaccines are safe and effective, and their use should be maximized.
- Future influenza vaccine candidates, including live attenuated and novel antigen-based vaccines, show promise for improved administration and longer-lasting immunity, potentially requiring adjuvant enhancement.
- Continued efforts are needed to improve influenza prevention and control strategies globally.